Breaking News, Collaborations & Alliances

ReiThera Partners with SillaJen to Develop & Produce the SJ-600 Series for Clinical Trials

Will transform SillaJen’s anticancer virus platform into a clinical-ready drug capable of entering trials.

Author Image

By: Charlie Sternberg

Associate Editor

ReiThera has inked a comprehensive Master Service Agreement (MSA) with SillaJen, which establishes ReiThera as the manufacturing partner for SillaJen’s anticancer virus platform, the SJ-600 series. Under this agreement, ReiThera will leverage its expertise to conduct advanced development and GMP production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials. As a global Contract Development and Manufacturing Organization (CDMO) based in Italy, ReiThe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters